Ferozsons Laboratories Limited, a publicly listed healthcare company has partnered with PanTheryx Inc. an innovative US life science company, to launch DiaResQ sachets, a breakthrough nutritional innovation for diarrhoea relief in children and adults. The product was included among the world’s 30 leading healthcare innovations that show promise in transforming global health by 2030, in the “Reimagining Global Health, Innovation Countdown 2030” report, produced by PATH, and supported by Bill & Melinda Gates Foundation, USAID and Ministry of Foreign Affairs, Norway.1 DiaResQ gives physicians an option for a highly effective nature-based treatment of diarrhoea, a disease that according to the Pakistan Demographic and Health Survey, claims around 53,000 lives of children under the age of 5 annually. However, most experts believe that the figure is much higher and hovers between 100,000-125,000 annual deaths.
Scott Hyman, the Senior Vice President of PanTheryx, Inc. said, “At PanTheryx, we believe that GI health is a basic right of all people, regardless of their socio-economic status and we are totally dedicated to insuring that even the poorest and hardest to reach populations have access to our products. Our partnership with Ferozsons and the launch of DiaResQ in Pakistan is a true milestone for us as we work to fulfill that mission. As a company, they share our vision for the vast potential that nutritional interventions have to reduce the high number of deaths due to diarrhoeal disease, and to to dramatically impact the burden caused by diarrhoea improving the overall quality of life for families across Pakistan.”
DiaResQ supplements use of oral rehydration solution and zinc by providing nutrients for intestinal repair. Most children that suffer from diarrhoea in Pakistan are also reported to be malnourished.
According to a study published by the British Medical Journal (BMJ), demonstrated the efficacy of DiaResQ in treating acute childhood diarrhoea caused by the most common pathogens. Ninety-six percent (96%) of the diarrhoea cases resolved with one dose of DiaResQ taken for three days – it significantly reduced fifty-six percent (56%) diarrhea episodes at day 1 of treatment as well.
Osman Khalid Waheed, the CEO of Ferozsons Laboratories Limited said, “Ferozsons is a patient-centered company committed to introducing breakthrough therapies in a number of challenging disease areas in Pakistan. We have recently started working in mother and child health with international partners like PanTheryx, Inc. and are confident that such innovations will contribute to reducing child mortality and ultimately help Pakistan achieve its Sustainable Development Goals around health.”
DiaResQ is recommended for children above 6 months of age and is currently available across Asia and Africa in addition to the United States.